...
首页> 外文期刊>Journal of experimental & clinical cancer research : >Ultrasound microbubble-mediated delivery of the siRNAs targeting MDR1 reduces drug resistance of yolk sac carcinoma L2 cells
【24h】

Ultrasound microbubble-mediated delivery of the siRNAs targeting MDR1 reduces drug resistance of yolk sac carcinoma L2 cells

机译:超声微泡介导的靶向MDR1的siRNA传递降低了卵黄囊癌L2细胞的耐药性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background MDR1 gene encoding P-glycoprotein is an ATP-dependent drug efflux transporter and related to drug resistance of yolk sac carcinoma. Ultrasound microbubble-mediated delivery has been used as a novel and effective gene delivery method. We hypothesize that small interfering RNA (siRNA) targeting MDR1 gene (siMDR1) delivery with microbubble and ultrasound can down-regulate MDR1 expression and improve responsiveness to chemotherapeutic drugs for yolk sac carcinoma in vitro. Methods Retroviral knockdown vector pSEB-siMDR1s containing specific siRNA sites targeting rat MDR1 coding region were constructed and sequence verified. The resultant pSEB-siMDR1 plasmids DNA were encapsulated with lipid microbubble and the DNA release were triggered by ultrasound when added to culture cells. GFP positive cells were counted by flow cytometry to determine transfection efficiency. Quantitative real-time PCR and western blot were performed to determine the mRNA and protein expression of MDR1. P-glycoprotein function and drug sensitivity were analyzed by Daunorubicin accumulation and MTT assays. Results Transfection efficiency of pSEB-siMDR1 DNA was significantly increased by ultrasound microbubble-mediated delivery in rat yolk sac carcinoma L2 (L2-RYC) cells. Ultrasound microbubble-mediated siMDR1s delivery effectively inhibited MDR1 expression at both mRNA and protein levels and decreased P-glycoprotein function. Silencing MDR1 led to decreased cell viability and IC50 of Vincristine and Dactinomycin. Conclusions Our results demonstrated that ultrasound microbubble-mediated delivery of MDR1 siRNA was safe and effective in L2-RYC cells. MDR1 silencing led to decreased P-glycoprotein activity and drug resistance of L2-RYC cells, which may be explored as a novel approach of combined gene and chemotherapy for yolk sac carcinoma.
机译:背景编码P糖蛋白的MDR1基因是ATP依赖的药物外排转运蛋白,与卵黄囊癌的耐药性有关。超声微泡介导的传递已被用作一种新颖而有效的基因传递方法。我们假设以微泡和超声为靶标的靶向MDR1基因(siMDR1)的小干扰RNA(siRNA)可以下调MDR1的表达并提高卵黄囊癌对化疗药物的反应性。方法构建具有针对大鼠MDR1编码区的特异性siRNA位点的逆转录病毒敲低载体pSEB-siMDR1,并进行序列验证。用脂质微泡将所得的pSEB-siMDR1质粒DNA包裹起来,添加到培养细胞后,超声触发DNA释放。通过流式细胞术计数GFP阳性细胞以确定转染效率。进行实时定量PCR和western印迹以确定MDR1的mRNA和蛋白表达。通过柔红霉素积累和MTT分析来分析P-糖蛋白功能和药物敏感性。结果超声微泡介导的传递在大鼠卵黄囊癌L2(L2-RYC)细胞中显着提高了pSEB-siMDR1 DNA的转染效率。超声微泡介导的siMDR1的传递有效地抑制了MDR1在mRNA和蛋白质水平上的表达,并降低了P糖蛋白的功能。沉默MDR1会导致长春新碱和放线菌素的细胞活力降低,IC 50 降低。结论我们的结果表明,超声微泡介导的MDR1 siRNA递送在L2-RYC细胞中是安全有效的。 MDR1沉默导致P2-糖蛋白活性降低和L2-RYC细胞耐药,这可能是卵黄囊癌基因和化疗联合的新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号